IDL Diagnostics AB (publ) (FRA:80R)

Market Cap	8.18M
Revenue (ttm)	4.72M
Net Income (ttm)	-4.44M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0246
Previous Close	0.0240
Day's Range	0.0246 - 0.0246
52-Week Range	0.0196 - 0.0548
Beta	n/a
RSI	49.83
Earnings Date	Feb 24, 2026

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, S...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 80R

Financial Performance

In 2024, IDL Diagnostics AB's revenue was 57.44 million, an increase of 33.45% compared to the previous year's 43.04 million. Losses were -42.45 million, -28.41% less than in 2023.

Financial numbers in SEK